Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 212Pb-ADVC001
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
Details : The collaboration aims on the development of a global 212Pb radioisotope and radioligand supply chain to specifically support the development and commercialization of 212Pb-labeled radioligands including, 212Pb-ADVC001, a best-in-class treatment for meta...
Brand Name : 212Pb-ADVC001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 26, 2023
Lead Product(s) : 212Pb-ADVC001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 212Pb-ADVC001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Morningside
Deal Size : $18.0 million
Deal Type : Series B Financing
AdvanCell Closes A $18M Series B Funding Led by Morningside
Details : Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs.
Brand Name : 212Pb-ADVC001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 23, 2022
Lead Product(s) : 212Pb-ADVC001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Morningside
Deal Size : $18.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?
Reset All
